← Leaderboards
Qiang Shen
Baylor College Of Medicine
$4,673,856
Attributed
$4,673,856
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $976.2K · FY2009–23$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$4,673,856 · 3
By mechanism
R01$4,270,681 · 2
K22$403,175 · 1
Top collaborators
No co-investigators on record.
Most similar at Baylor College Of Medicine
Same institution · by research overlap
- Powel H Brown$10,794,797
- David R Rowley$11,107,276
- Yi Li$11,171,360
- Susan G. Hilsenbeck$11,246,744
- Min Li$6,971,652
Others in their field
Top investigators on “Estrogen Receptor Negative”
- Matthew J Ellis · Duke University$10,610,833
- Ellen M Velie · Michigan State University$10,395,017
- Sally Radovick · Children'S Hospital Boston$9,827,849
- Wei Zheng · Roswell Park Cancer Institute Corp$9,087,356
- Xiang Zhang · Sloan-Kettering Inst Can Research$8,197,930
- Christine B. Ambrosone · Roswell Park Cancer Institute Corp$7,920,246
Research focus
Estrogen Receptor NegativeEstrogen Receptor PositiveMouse ModelMalignant Breast NeoplasmIn VitroBreast Cancer CellIn VivoMalignant NeoplasmsOrganFoundationsMammary NeoplasmsCellsCancer TherapyMammary GlandEstrogen ReceptorsAromatase InhibitorsAnalogClinical DevelopmentClinically RelevantFluoresceinBiotinComplexEstrogen AntagonistsAnimal Model
Grant awards (16)
Chemoprevention of Breast Cancer by Targeting Glucose Metabolism with HJC0152$329,600
R01 · FY2023 · CA · contact PI
Targeting Glucose Metabolism with HJC0152 for Treating Metastatic Breast Cancer$240,557
R01 · FY2023 · CA · contact PI
Chemoprevention of Breast Cancer by Targeting Glucose Metabolism with HJC0152$535,020
R01 · FY2022 · CA · contact PI
Targeting Glucose Metabolism with HJC0152 for Treating Metastatic Breast Cancer$441,162
R01 · FY2022 · CA · contact PI
Targeting Glucose Metabolism with HJC0152 for Treating Metastatic Breast Cancer$424,168
R01 · FY2021 · CA · contact PI
Chemoprevention of Breast Cancer by Targeting Glucose Metabolism with HJC0152$1
R01 · FY2021 · CA · contact PI
Chemoprevention of Breast Cancer by Targeting Glucose Metabolism with HJC0152$452,885
R01 · FY2020 · CA · contact PI
Targeting Glucose Metabolism with HJC0152 for Treating Metastatic Breast Cancer$1
R01 · FY2020 · CA · contact PI
Chemoprevention of Breast Cancer by Targeting Glucose Metabolism with HJC0152$450,058
R01 · FY2019 · CA · contact PI
Targeting Glucose Metabolism with HJC0152 for Treating Metastatic Breast Cancer$440,093
R01 · FY2019 · CA · contact PI
Targeting Glucose Metabolism with HJC0152 for Treating Metastatic Breast Cancer$478,639
R01 · FY2018 · CA · contact PI
Chemoprevention of Breast Cancer by Targeting Glucose Metabolism with HJC0152$478,497
R01 · FY2018 · CA · contact PI
TARGETING THE AP-1 TRANSCRIPTION FACTOR TO PREVENT METASTASIS FROM BREAST CANCER$137,434
K22 · FY2011 · CA · contact PI
TARGETING THE AP-1 TRANSCRIPTION FACTOR TO PREVENT METASTASIS FROM BREAST CANCER$133,449
K22 · FY2010 · CA · contact PI
TARGETING THE AP-1 TRANSCRIPTION FACTOR TO PREVENT METASTASIS FROM BREAST CANCER$131,100
K22 · FY2009 · CA · contact PI
TARGETING THE AP-1 TRANSCRIPTION FACTOR TO PREVENT METASTASIS FROM BREAST CANCER$1,192
K22 · FY2009 · CA · contact PI